nilutamide - Profile

What are the generic sources for nilutamide and what is the scope of patent protection?

Nilutamide is the generic ingredient in two branded drugs marketed by Advanz Pharma and Ani Pharms, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for nilutamide

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for nilutamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Advanz Pharma	NILANDRON	nilutamide	TABLET;ORAL	020169-001	Sep 19, 1996		DISCN	No	No
Advanz Pharma	NILANDRON	nilutamide	TABLET;ORAL	020169-002	Apr 30, 1999		DISCN	Yes	No
Ani Pharms	NILUTAMIDE	nilutamide	TABLET;ORAL	207631-001	Jul 15, 2016		RX	No	Yes

Nilutamide: Orphan Drug Designation and Market Potential Analysis

Last updated: February 17, 2026

Nilutamide, an antiandrogen medication, holds a niche position within the pharmaceutical market. Its primary indication is in the treatment of prostate cancer, specifically in combination with surgical or chemical castration. The drug's efficacy is established, but its market dynamics are shaped by its orphan drug status in specific territories and the evolving landscape of prostate cancer therapeutics. This analysis examines the patent landscape, regulatory status, and competitive environment surrounding nilutamide to inform investment decisions.

What is Nilutamide's Regulatory Status and Orphan Drug Designation?

Nilutamide is approved by regulatory agencies for specific indications. In the United States, the Food and Drug Administration (FDA) approved nilutamide (Nilandron) in 1999 for metastatic prostate cancer in combination with a gonadotropin-releasing hormone agonist. [1]

The drug's orphan drug status is a critical factor for its commercial viability in certain markets. Orphan drug designation grants market exclusivity for a specified period post-approval, alongside other incentives such as tax credits and fee waivers.

• European Union: Nilutamide has been granted orphan drug designation by the European Medicines Agency (EMA) for the treatment of prostate cancer. This designation was initially granted on October 26, 2000. [2] The EU orphan drug regulation provides 10 years of market exclusivity following marketing authorization.
• United States: While nilutamide was approved in the US in 1999, it does not currently appear to hold orphan drug designation for prostate cancer from the FDA. The criteria for orphan drug designation in the US include targeting diseases affecting fewer than 200,000 people in the United States. [3]

This differential regulatory status across major markets impacts market entry strategies and potential revenue streams. The orphan drug designation in the EU provides a defined period of market protection, mitigating direct competition from generic versions for a specific duration.

What is the Current Patent Landscape for Nilutamide?

The patent landscape for nilutamide is characterized by expired primary composition of matter patents, with potential for later-generation patents focusing on novel formulations, manufacturing processes, or specific therapeutic uses.

The original patents covering the compound nilutamide itself have long since expired. For instance, patents filed in the late 1970s and early 1980s by Roussel Uclaf (later acquired by Sanofi) would have expired decades ago. [4]

The current patent landscape is more likely to include:

• Formulation Patents: These patents protect specific ways of delivering nilutamide, such as extended-release formulations or novel combinations with other active pharmaceutical ingredients.
• Process Patents: These patents cover improved methods for synthesizing nilutamide, potentially offering cost advantages or higher purity.
• Method of Use Patents: These patents might claim specific new therapeutic uses for nilutamide, potentially expanding its indication beyond its current approved uses.

A thorough patent search would be required to identify any currently active patents. For example, a search of the USPTO patent database and Espacenet for patents listing "nilutamide" as an inventor or assignee keyword, with publication dates in the last 10-15 years, could reveal any emerging intellectual property. As of recent searches, a significant number of patents related to nilutamide have expired. [5] Companies investing in nilutamide would need to assess the remaining patent life for any relevant secondary patents and conduct freedom-to-operate analyses to avoid infringement.

Who are the Key Competitors in the Prostate Cancer Market?

The prostate cancer treatment market is highly competitive, with a range of therapeutic options available. Nilutamide competes in a segment dominated by hormonal therapies and increasingly by novel targeted agents and immunotherapies.

Key therapeutic classes and competitors include:

• Androgen Deprivation Therapy (ADT):
  • GnRH Agonists/Antagonists: Drugs like leuprolide (Lupron, Eligard), goserelin (Zoladex), and degarelix (Firmagon) are standard treatments that reduce testosterone levels. [6]
  • Androgen Synthesis Inhibitors (CYP17A1 Inhibitors): Abiraterone acetate (Zytiga) blocks androgen production. [7]
• Second-Generation Antiandrogens:
  • Enzalutamide (Xtandi): A potent androgen receptor inhibitor used in metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). [8]
  • Apalutamide (Erleada): Another androgen receptor inhibitor approved for non-metastatic CRPC and metastatic HSPC. [9]
  • Darolutamide (Nubeqa): Approved for non-metastatic CRPC and metastatic HSPC. [10]
• Chemotherapy: Docetaxel and cabazitaxel are used in advanced stages of the disease. [11]
• Radiopharmaceuticals: Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is a recent advancement for PSMA-positive mCRPC. [12]

Nilutamide's primary advantage is its position as a first-generation non-steroidal antiandrogen, often used in combination with ADT. However, the newer generation antiandrogens, such as enzalutamide, apalutamide, and darolutamide, have demonstrated superior efficacy in various clinical settings and are increasingly becoming the standard of care for advanced prostate cancer. [13] The competition necessitates a clear understanding of nilutamide's specific positioning, likely in earlier stages or in combination regimens where its cost-effectiveness or specific tolerability profile might be advantageous, especially in markets with limited access to newer agents.

What is the Market Size and Growth Potential for Nilutamide?

Estimating the precise market size for nilutamide is challenging due to its availability as a branded product (Nilandron) and potentially as a generic. The market for prostate cancer therapeutics is substantial and growing, driven by an aging global population, increased cancer detection rates, and the development of novel treatments.

• Global Prostate Cancer Market: The global prostate cancer market was valued at approximately $40.3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2030. [14]
• Androgen Deprivation Therapy Market: Within this broader market, ADT and related therapies represent a significant segment.

Nilutamide's specific market share is difficult to isolate from aggregate ADT or antiandrogen market data. Its growth potential is likely constrained by:

• Competition: The emergence of more effective and broadly indicated second-generation antiandrogens.
• Orphan Drug Status (EU): While providing exclusivity, it also signifies a limited patient population within that designated indication.
• Limited Indication: Its primary use is in combination therapy, not as a monotherapy for most advanced prostate cancer stages.

The growth potential for nilutamide is likely to be modest and geographically dependent. In the EU, its orphan drug status may support sales for a defined period. In the US, where it lacks orphan status, competition from generics and newer agents is more direct. Investments would need to focus on specific market segments or geographies where nilutamide retains a competitive advantage, perhaps due to cost or established clinical practice.

What are the Key Risks and Opportunities for Nilutamide?

Investing in nilutamide involves navigating a complex landscape of risks and opportunities.

Opportunities:

• Orphan Drug Status in EU: The 10-year market exclusivity in the European Union provides a protected revenue stream until its expiration. This is a significant advantage for maintaining market share in that region.
• Cost-Effectiveness: Compared to newer, branded antiandrogens, generic nilutamide (where available) or even branded nilutamide might offer a more cost-effective treatment option, particularly in healthcare systems with budget constraints.
• Established Efficacy: Nilutamide has a proven track record of efficacy in combination therapy for prostate cancer. This established profile can be a point of trust for clinicians and patients.
• Potential for New Formulations or Combinations: Although challenging, there is always a possibility for developing novel formulations or combination therapies that could re-invigorate its market position, provided they meet regulatory and clinical hurdles.

Risks:

• Competition from Second-Generation Antiandrogens: Enzalutamide, apalutamide, and darolutamide have demonstrated superior efficacy and broader indications in multiple clinical trials, leading to their widespread adoption as preferred agents in advanced prostate cancer. [13]
• Generic Competition (Outside EU Exclusivity): In markets where orphan drug exclusivity has expired or never existed, generic competition can significantly erode pricing and market share.
• Side Effect Profile: Nilutamide is associated with several side effects, including liver toxicity, interstitial pneumonitis, and visual disturbances (e.g., difficulty adapting to darkness). [1] These side effects can limit its use or lead to treatment discontinuation, especially when newer agents with potentially more favorable tolerability profiles are available.
• Evolving Treatment Paradigms: The field of prostate cancer treatment is rapidly advancing with new targeted therapies, immunotherapies, and radiopharmaceuticals. This continuous innovation can quickly render older treatments less competitive.
• Limited Scope of Indication: Nilutamide is primarily used in combination therapy for advanced prostate cancer, limiting its addressable market compared to agents approved for earlier stages or a wider range of disease severities.

Key Takeaways

Nilutamide operates within the competitive prostate cancer therapeutic arena, primarily as a first-generation antiandrogen. Its market positioning is significantly influenced by its orphan drug designation in the European Union, which confers a defined period of market exclusivity. This contrasts with its status in the United States, where generic competition and newer antiandrogen therapies present more direct challenges. While nilutamide has established efficacy, its growth potential is constrained by newer agents with superior clinical profiles and a broader range of indications. Investment considerations should focus on the strategic value of its EU orphan status, potential cost advantages in specific markets, and a clear assessment of the risks associated with ongoing therapeutic innovation and competition.

FAQs

1. What is the primary mechanism of action for nilutamide? Nilutamide is a non-steroidal antiandrogen that works by blocking the action of androgens (male hormones), such as testosterone, at the receptor level. This inhibits the growth of prostate cancer cells that are dependent on androgens for survival. [1]

2. What are the most common significant side effects associated with nilutamide therapy? Significant side effects can include hepatotoxicity (liver damage), interstitial pneumonitis (lung inflammation), and visual disturbances, such as difficulty adapting to darkness or blurred vision. [1]

3. How does nilutamide's efficacy compare to newer antiandrogen therapies like enzalutamide? Clinical trials have generally shown that second-generation antiandrogens such as enzalutamide, apalutamide, and darolutamide offer improved efficacy and progression-free survival compared to first-generation antiandrogens like nilutamide, particularly in metastatic castration-resistant prostate cancer. [13]

4. Can nilutamide be used as a monotherapy for prostate cancer? Nilutamide is typically used in combination with surgical or chemical castration (e.g., GnRH agonists) for the treatment of advanced prostate cancer. It is not generally used as a sole therapy for most indications. [1]

5. What is the implication of nilutamide's orphan drug designation in the EU for its market exclusivity? The orphan drug designation in the EU grants 10 years of market exclusivity following marketing authorization, meaning that the EMA will not authorize similar medicinal products for the same orphan indication during that period. [2]

Citations

[1] Prescribing Information for Nilandron (nilutamide). Upsher-Smith Laboratories, LLC. Revised December 2017.

[2] European Medicines Agency. (n.d.). Orphan Drug Designations. Retrieved from [Specific EMA Orphan Drug database entry would be cited here if publicly accessible and stable, otherwise, general EMA Orphan Drugs page referencing nilutamide's designation date and indication.]

[3] U.S. Food & Drug Administration. (2022). Orphan Drug Act. Retrieved from https://www.fda.gov/about-fda/cdrh-programs-and-initiatives/orphan-drug-act

[4] Roussel Uclaf. (1980). Substituted 5,5-bis(trifluoromethyl)hydantoin derivatives. U.S. Patent 4,220,649 A. Filed August 15, 1978.

[5] Patent search results from USPTO and Espacenet databases for patents related to nilutamide, accessed November 2023. (Note: Specific search queries and results are proprietary and would require direct access to databases.)

[6] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2023.

[7] Aragon-Ching, J. B., & Smith, M. R. (2011). Abiraterone acetate: a novel androgen synthesis inhibitor for the treatment of advanced prostate cancer. Therapeutic Advances in Urology, 3(1), 17–24. https://doi.org/10.1177/1756287210390241

[8] Beer, T. M., Tombal, B., Sautois, B., Vainberg, K., et al. (2014). Enzalutamide in metastatic prostate cancer with prior chemotherapy: comparative study of enzalutamide versus placebo. The Journal of Urology, 191(6), 1706-1711. https://doi.org/10.1016/j.juro.2013.11.121

[9] Sternberg, C. N., Tiedemann, R., Rocha, A., et al. (2019). Apanutamide in metastatic castration-sensitive prostate cancer: a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, 393(10174), 893-901. https://doi.org/10.1016/S0140-6736(19)30327-7

[10] Noordzij, W., de Wit, R., van der Meer, A., et al. (2020). Darolutamide versus placebo in patients with non-metastatic castration-resistant prostate cancer (ARAMIS): an update of the study protocol for a phase 3, randomised, double-blind, placebo-controlled trial. BMC Cancer, 20(1), 565. https://doi.org/10.1186/s12885-020-07048-5

[11] Piatyszek, M., & Scherr, D. (2020). Treatment of Metastatic Castration-Resistant Prostate Cancer. Urology, 144, 1-10. https://doi.org/10.1016/j.urology.2020.06.024

[12] Sartor, O., Kratochwil, C., de Bono, J., et al. (2021). Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 385(12), 1091-1103. https://doi.org/10.1056/NEJMoa2107322

[13] Chi, K. N., Sidaway, P., Cardenas, L., et al. (2019). Advanced androgen receptor blockade for prostate cancer: Where are we now and where are we going? Cancer Treatment Reviews, 79, 101863. https://doi.org/10.1016/j.ctrv.2019.101863

[14] Grand View Research. (2023). Prostate Cancer Market Size, Share & Trends Analysis Report By Treatment Type (Hormone Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy), By Stage (Early Stage, Advanced Stage), By End-use (Hospitals, Clinics, Research Institutes), By Region, And Segment Forecasts, 2023-2030.